February 6, 2014, Neurocrine Biosciences (NBIX) reported financial results for the fourth quarter and full year ended 2013. The company reported total revenues in the fourth quarter of $0.73 million, dead-on with our expectations. Revenues have been pegged at around $0.7 million for all four quarters in 2013. Research and development expenses were $8.9 million, around $0.6 million below our estimate. General and administrative expenses of $3.3 million came in essentially right in-line with our model. The company reported a loss of $10.6 million ($0.16 per share) for the quarter, roughly $0.01 better than our expectation of ($0.17) on slightly lower R&D.
For the full year 2013, revenues totaled $2.9 million, a sizable drop from the $53.1...
Only subscribers can access this article, which is part of the PRO research library covering 3,577 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: